<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="568">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243280</url>
  </required_header>
  <id_info>
    <org_study_id>M14-867</org_study_id>
    <secondary_id>2014-002925-36</secondary_id>
    <nct_id>NCT02243280</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 4, 5, and 6 Infection (SURVEYOR-I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Canada: Health Canada</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>New Zealand: Medsafe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to evaluate the efficacy, safety, and pharmacokinetics of
      co-administration of ABT-493 and ABT-530 with and without ribavirin in subjects with HCV
      Genotype 1, 4, 5, and 6 infection.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with sustained virologic response (SVR) 12</measure>
    <time_frame>Up to Week 12 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with sustained virologic response (SVR) 4</measure>
    <time_frame>Up to 4 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with virologic failure during treatment</measure>
    <time_frame>Up to last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with quantifiable hepatitis C virus ribonucleic acid at the end of treatment, confirmed quantifiable hepatitis C virus ribonucleic acid after previously having unquantifiable hepatitis C virus ribonucleic acid, or a confirmed increase of at least one log10 in hepatitis C virus ribonucleic acid during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Post-Treatment relapse</measure>
    <time_frame>Within 12 weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with confirmed quantifiable hepatitis C virus ribonucleic acid after completion of treatment among subjects with unquantifiable hepatitis C virus ribonucleic acid at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatitis C Virus</condition>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose A) + ABT-530 (Dose A) for 12 weeks in HCV genotype 1 infected subjects without cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose A) + ABT-530 (Dose B) for 12 weeks in HCV genotype 1 infected subjects without cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) for 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose A) + ABT-530 (Dose A) for 8 weeks in HCV genotype 1 infected subjects without cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) for 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose A) + ABT-530 (Dose B) for 8 weeks in HCV genotype 1 infected subjects without cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose A) + ABT-530 (Dose A) + RBV for 12 weeks in HCV genotype 1 infected subjects with cirrhosis (randomized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) (randomized)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose A) + ABT-530 (Dose A) for 12 weeks in HCV genotype 1 infected subjects with cirrhosis (randomized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose A) + ABT-530 (Dose B) + RBV for 12 weeks in HCV genotype 1 infected subjects with cirrhosis (randomized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) (randomized)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose A) + ABT-530 (Dose B) for 12 weeks in HCV genotype 1 infected subjects with cirrhosis (randomized)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose B) + ABT-530 (Dose A) for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose B) + ABT-530 (Dose A) for 12 weeks in HCV genotype 4, 5, and 6 infected subjects without cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose A) + ABT-530 (Dose B) for 12 weeks in HCV genotype 4, 5, and 6 infected subjects without cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 (Dose B) + ABT-530 (Dose A) for 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 (Dose B) + ABT-530 (Dose A) for 8 weeks in HCV genotype 1 infected subjects without cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493</intervention_name>
    <description>Tablets</description>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) for 8 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) for 8 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) + RBV</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) (randomized)</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) + RBV</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) (randomized)</arm_group_label>
    <arm_group_label>ABT-493 (Dose B) + ABT-530 (Dose A) for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B)</arm_group_label>
    <arm_group_label>ABT-493 (Dose B) + ABT-530 (Dose A) for 8 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-530</intervention_name>
    <description>Tablets</description>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) for 8 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) for 8 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) + RBV</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose A) (randomized)</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) + RBV</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B) (randomized)</arm_group_label>
    <arm_group_label>ABT-493 (Dose B) + ABT-530 (Dose A) for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493 (Dose A) + ABT-530 (Dose B)</arm_group_label>
    <arm_group_label>ABT-493 (Dose B) + ABT-530 (Dose A) for 8 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between 18 and 70 years of age, inclusive, at time of screening.

          2. Screening laboratory result indicating HCV GT1, GT4, GT 5, or GT6 infection.

          3. Chronic HCV infection.

          4. Subject must be either HCV treatment-naïve or combination of pegylated-interferon
             ribavirin experienced.

          5. Subjects must be documented as non-cirrhotic or cirrhotic.

        Exclusion Criteria:

          1. History of severe, life-threatening or other significant sensitivity to any drug.

          2. Female who is pregnant, planning to become pregnant during the study or
             breastfeeding; or male whose partner is pregnant or planning to become pregnant
             during the study.

          3. Recent (within 6 months prior to study drug administration) history of drug or
             alcohol abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          4. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or
             anti-human immunodeficiency virus antibody (HIV Ab).

          5. HCV genotype performed during screening indicating co-infection with more than one
             HCV genotype.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armen Asatryan, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130701</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130715</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130686</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132236</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130683</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130712</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130714</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131531</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130704</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130685</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130689</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130703</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130681</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132215</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130682</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130687</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132589</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130707</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132237</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130688</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131528</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132591</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130696</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135948</name>
      <address>
        <city>Brisbane, Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135893</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130695</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130691</name>
      <address>
        <city>Fitzroy, Melbourne</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130697</name>
      <address>
        <city>Kingswood</city>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130693</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130680</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130692</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130674</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130675</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130672</name>
      <address>
        <city>Montreal</city>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130673</name>
      <address>
        <city>Vaughan</city>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130716</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130718</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130699</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130724</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130729</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130809</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130812</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130850</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130810</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130856</name>
      <address>
        <city>Auckland</city>
        <zip>1150</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135895</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130857</name>
      <address>
        <city>Dunedin, Otago</city>
        <zip>9054</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130859</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130858</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130679</name>
      <address>
        <city>Bayamon</city>
        <zip>00959</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130678</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130677</name>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132068</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137254</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130862</name>
      <address>
        <city>Majadahonda, Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130860</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130877</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 10, 2015</lastchanged_date>
  <firstreceived_date>September 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhotic</keyword>
  <keyword>HCV GT6</keyword>
  <keyword>Hepatitis C Genotype 4 (GT 4)</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV GT4</keyword>
  <keyword>Hepatitis C Genotype 5 (GT 5)</keyword>
  <keyword>Hepatitis C virus</keyword>
  <keyword>HCV GT1</keyword>
  <keyword>Interferon (IFN) Free</keyword>
  <keyword>Hepatitis C Genotype 1 (GT1)</keyword>
  <keyword>IFN free</keyword>
  <keyword>HCV GT5</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Hepatitis C Genotype 6 (GT 6)</keyword>
  <keyword>Child Pugh A</keyword>
  <keyword>RBV</keyword>
  <keyword>Compensated Cirrhosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
